Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR 1,350.00
+21.65 (1.63%)
At close: Jun 25, 2026
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 39 analysts polled by S&P Global, Dr. Reddy's Laboratories stock has a consensus rating of "Hold" and an average price target of ₹1,332. The average 1-year stock price forecast is 1.35% lower than the current stock price, while the lowest is ₹1,040 (-22.96%) and the highest is ₹1,750 (+29.63%).
Price Target: ₹1,332 (-1.35%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 11 | 12 | 11 | 12 | 12 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 10 | 11 | 10 | 10 | 10 | 10 |
| Sell | 7 | 7 | 7 | 7 | 6 | 6 |
| Strong Sell | 6 | 5 | 5 | 6 | 6 | 6 |
| Total | 39 | 38 | 38 | 38 | 39 | 39 |
Financial Forecast
Revenue This Year
357.54B
from 335.93B
Increased by 6.43%
Revenue Next Year
394.36B
from 357.54B
Increased by 10.30%
EPS This Year
52.91
from 55.39
Decreased by -4.47%
EPS Next Year
64.48
from 52.91
Increased by 21.86%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 390.4B | ||
| Avg | 357.5B | ||
| Low | 334.2B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 16.2% | ||
| Avg | 6.4% | ||
| Low | -0.5% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 68.40 | ||
| Avg | 52.91 | ||
| Low | 41.20 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 23.5% | ||
| Avg | -4.5% | ||
| Low | -25.6% |